問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Orthopedics

Division of General Surgery

Division of Hematology & Oncology

National Taiwan University Cancer Center (在職)

Division of Orthopedics

Division of Hematology & Oncology

更新時間：2023-09-19

楊士弘YANG, SHIH-HUNG
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

楊士弘

List

62Cases

2024-03-01 - 2026-12-31

Phase I

臨床一期、開放性、劑量探索之試驗，旨在評估LBL-01注射劑用於晚期實體腫瘤患者安全性、耐受性、藥物動力學與初步療效

  • Condition/Disease

    晚期實體腫瘤

  • Test Drug

    LBL-01 Injection

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2021-03-01 - 2023-04-15

Phase II

A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Atezolizumab(TecentriqR) Bevacizumab(AvastinR)

Participate Sites
3Sites

Terminated3Sites

2012-10-01 - 2017-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2012-09-01 - 2017-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2013-03-01 - 2020-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-03-01 - 2020-12-31

Others

A PHASE Ib/III, OPEN-LABEL, MULTICOHORT, MULTICENTER, STUDY EVALUATING THE EFFICACY AND SAFETY OF RO6958688 PLUS ATEZOLIZUMAB, WITH OR WITHOUT CHEMOTHERAPY IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

  • Condition/Disease

    METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

  • Test Drug

    RO6958688、Tecentriq、Onivyde、Leucovorin、Abraxane、Fluorouracil (5-FU)、Gemcitabine

Participate Sites
3Sites

Terminated3Sites

2021-07-01 - 2022-08-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2012-03-01 - 2014-06-30

Phase II

A Phase IIa Multi-centre Randomised Double-Blind Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of AZD8931 in Combination with Paclitaxel versus Paclitaxel alone in Patients with Metastatic, Gastric or Gastro-oesophageal Junction, Cancer who progress following First Line Therapy and are Ineligible for Treatment with trastuzumab by HER2 Status (SAGE)

  • Condition/Disease

    Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD8931

Participate Sites
5Sites

Terminated4Sites

Study ended1Sites

2011-12-01 - 2016-07-31

Phase II

A Randomised Open-Label Phase IIa Study to Assess the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric or Gastro-oesophageal Junction Cancer with FGFR2 Polysomy or Gene Amplification (Shine study)

  • Condition/Disease

    Advanced Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD4547

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

2015-05-01 - 2020-06-11

Phase II

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

  • Condition/Disease

    Glioblastoma Multiforme (GBM)

  • Test Drug

    ABT-414

Participate Sites
5Sites

Terminated5Sites

魏國珍
Linkou Chang Gung Medical Foundation

Division of Orthopedics

1 2 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB